Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CD83 CAR T in Relapsed or Refractory Acute Myeloid Leukemia (AML): A Phase I Trial

NCT06871410 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.

NCT NCT06871410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06871410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CD83 CAR T in Relapsed or Refractory Acute Myeloid Leukemia (AML): A Phase I Trial
Lead sponsor
Roswell Park Cancer Institute
Phase
Phase 1
Overall status
Recruiting
Start date
February 2, 2026
Completion date
April 1, 2028
Enrollment
26 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent acute myeloid leukemia, refractory acute myeloid leukemia